Employers Look to PBMs for Lower Drug Costs and Better Access | iPharmaCenter

Saudi SFDA Launches NADR Program to Accelerate Rare Disease Drug Access

Saudi Arabia Grants World’s First Approval for Iberdomide in Multiple Myeloma | iPharmaCenter

FDA Grants Accelerated Approval to Zenbexus Combination for Relapsed Multiple Myeloma | iPharmaCenter

Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter

Top 10 Pharma Companies by Revenue in 2025 | iPharmaCenter

China: NMPA Approves New Therapies | 2026

Italy | AIFA | Healthcare Updates | iPharmaCenter

ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026

Italy’s Medicine Spending Reaches €39.3 Billion in 2025 | iPharmaCenter

NICE Backs Acalabrutinib for Mantle Cell Lymphoma and Untreated CLL

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

FDA clears Pluvicto earlier in PSMA positive metastatic prostate cancer

EU Approves Datroway as 1L Monotherapy in PD‑1/PD‑L1–Ineligible Metastatic TNBC After TROPION‑Breast02 Survival Gain

UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy

UnitedHealth Scales Tennessee Health Hubs with $4M to Reach 200,000 Residents by 2027

European Commission Authorizes RINVOQ for Severe Alopecia Areata

AstraZeneca's trastuzumab deruxtecan approved by CDSCO for adults with HER2-positive Stage II or III early breast cancer | iPharmaCenter

Johnson & Johnson Expands Oncology and Immunology Pipelines via Multi-Billion-Dollar Deals | iPharmaCenter

FDA Approves Otsuka’s SIMTRIYO as First-in-Class NDSRI for ADHD

Sanofi Terminates Amlitelimab Development in Atopic Dermatitis | iPharmaCenter

Takeda Secures Landmark Approval for Orzeyful in China | iPharmaCenter

FDA Approves Jideytro for Previously Treated ROS1 Positive Non Small Cell Lung Cancer

India's CDSCO Grants Regulatory Approval for Takeda’s Qdenga Dengue Vaccine

CMS Outlines Operational Path for 2028 Maximum Fair Price Compliance

CMS Targets Fee-for-Service Fragmentation in New 2027 Policy Roadmap

Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter

FDA Approves First Oral PCSK9 Inhibitor, Signaling Shift in Dyslipidemia Treatment

American Academy of Dermatology (AAD) Innovation Academy 2026

Eli Lilly to Acquire AtaiBeckley for Up to $3.8 Billion, Expanding Psychedelic Neuroscience Pipeline

European Commission Grants Approval for Oral Semaglutide in Weight Management

Aetna Survey Highlights Evolving Payer-Provider Confidence Landscape | iPharmaCenter

FDA Grants Landmark Approval for REVTORPYK: A New Standard for PIK3CA Wild-Type Breast Cancer

CMS Proposes Major Medicare Overhaul: Shifting Toward Accountable Care and Value-Based Payments

Germany Enacts 2026 Healthcare Reform to Curb Statutory Insurance Spending

AstraZeneca Bolsters Oncology Pipeline with Global Acquisition of Zegfrovy

FDA Approval of Sarclisa Escena Marks Shift Toward Subcutaneous Oncology Delivery | iPharmaCenter

Navigating the Shift: Employer-Led Demands Reshape Pharmacy Benefit Management

FDA Approves KEYTRUDA-Padcev Combo as First Perioperative Standard for Muscle-Invasive Bladder Cancer

CMS 2027 Overhaul: Restructuring the Economics of Outpatient Care

Vertex moves to buy Crinetics in $10 billion endocrinology deal | iPharmaCenter

Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter

Optum Financial Adds Alegeus Platform To Deepen Consumer Health Benefits And Payments | iPharmaCenter

Myricx Bio Deal Brings Novel N‑Myristoyltransferase Inhibitor ADCs Into Novartis Portfolio | iPharmaCenter

Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours | iPharmaCenter

European Academy of Neurology (EAN) Congress 2026 | iPharmaCenter

ESMO Gastrointestinal Cancers Congress 2026 | iPharmaCenter

NICE Opens Access to New Immunotherapy in Cervical Cancer and First Disease‑Modifying Drug in Early Type 1 Diabetes

Hospital and Drug Costs Outpace Contributions in Germany, Raising Pressure on Pharma Pricing

CVS Pharmacy Joins Medicare GLP-1 Bridge and Scales Weight‑Loss Access Across the U.S. | iPharmaCenter